Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Business Conference participation

Ensysce Biosciences Conference Participation Announcement

Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026

Sentiment
0
Attention
0
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is routine and unlikely to materially affect Ensysce's stock price. It signals ongoing investor engagement and potential regulatory developments in psychedelic therapeutics, but no immediate financial impact is expected.

Biotechnology Pharmaceuticals

Forte Biosciences, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences and industry events in September 2026. These include the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, an FDA public hearing on psychedelic drug therapeutics, the Life Sciences Product Launch Summit, and the 20th Annual Pain Therapeutics Summit. The company will present at the Cantor conference and will hold one-on-one meetings with investors. Ensysce is developing neuroplastogenic therapies for chronic pain and novel opioids with reduced abuse potential.

stock
Ensysce announced its participation in multiple conferences and events, which may increase visibility among investors and industry stakeholders. No material change in fundamentals.
Importance 100.0 Sentiment 0.0
govactor
The FDA is holding a public hearing on psychedelic drug therapeutics, which Ensysce will attend; this could influence future regulatory pathways for its psychedelic-based therapies.
Importance 30.0 Sentiment 0.0
priv
Cantor Fitzgerald is hosting a healthcare conference where Ensysce will present, providing a platform for investor engagement.
Importance 20.0 Sentiment 0.0
priv
H.C. Wainwright is hosting an investment conference that Ensysce will attend, facilitating potential investor meetings.
Importance 20.0 Sentiment 0.0
exch
Ensysce is listed on Nasdaq; the announcement does not affect the exchange itself.
Importance 10.0 Sentiment 0.0
per
Lynn Kirkpatrick is the CEO of Ensysce and is listed as a company contact; her role is unchanged.
Importance 10.0 Sentiment 0.0
per
Geoff Birkett is chairperson of the Life Sciences Product Launch Summit, an event Ensysce will attend.
Importance 5.0 Sentiment 0.0
per
William Schmidt chairs the Pain Therapeutics Summit, which Ensysce will attend.
Importance 5.0 Sentiment 0.0
priv
MZ Group provides investor relations services for Ensysce, as indicated by the contact email.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.